LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 38

Suchoptionen

  1. Artikel: Que doivent savoir les chirurgiens à propos des troubles digestifs et des anomalies paracliniques induits par le COVID 19 ?

    Gornet, J-M / Tran Minh, M L / Leleu, F / Hassid, D

    Journal de chirurgie viscerale

    2020  Band 157, Heft 3, Seite(n) S52–S59

    Abstract: The symptoms associated with COVID-19 are mainly characterized by a triad composed of fever, dry cough and dyspnea. However, digestive symptoms have also been reportedAt first considered as infrequent, they in fact seem to affect more than half of ... ...

    Titelübersetzung What do surgeons need to know about the digestive disorders and paraclinical abnormalities induced by COVID-19?
    Abstract The symptoms associated with COVID-19 are mainly characterized by a triad composed of fever, dry cough and dyspnea. However, digestive symptoms have also been reportedAt first considered as infrequent, they in fact seem to affect more than half of patients. The symptoms are mainly manifested by anorexia, diarrhea, nausea and/or vomiting and abdominal pain. Even though prognosis is associated with lung injury, digestive symptoms seem significantly more frequent in patients presenting with severe COVID-19 infection. Digestive forms, which may be isolated or which can precede pulmonary symptoms, have indeed been reported, with diarrhea as a leading clinical sign. The main biological abnormalities that can suggest COVID-19 infection at an early stage are lymphopenia, elevated CRP and heightened ASAT transaminases. Thoraco-abdominal scan seems useful as a means of on the one hand ruling out digestive pathology unrelated to coronavirus and on the other hand searching for pulmonary images suggestive of COVID-19 infection. No data exist on the interest of digestive endoscopy in cases of persistent digestive symptoms. Moreover, the endoscopists may themselves be at significant risk of contamination. Fecal-oral transmission of the infection is possible, especially insofar as viral shedding in stools seems frequent and of longer duration than at the ENT level, including in patients with negative throat swab and without digestive symptoms. In some doubtful cases, virologic assessment of stool samples can yield definitive diagnosis. In the event of prolonged viral shedding in stools, a patient's persistent contagiousness is conceivable but not conclusively established. Upcoming serology should enable identification of the patients having been infected by the COVID-19 epidemic, particularly among previously undetected pauci-symptomatic members of a health care staff. Resumption of medico-surgical activity should be guided by dedicated strategy preceding deconfinement.
    Schlagwörter covid19
    Sprache Französisch
    Erscheinungsdatum 2020-04-27
    Erscheinungsland France
    Dokumenttyp English Abstract ; Journal Article ; Review
    ZDB-ID 2541648-0
    ISSN 1878-786X ; 0021-7697
    ISSN 1878-786X ; 0021-7697
    DOI 10.1016/j.jchirv.2020.04.013
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: What do surgeons need to know about the digestive disorders and paraclinical abnormalities induced by COVID-19?

    Gornet, J-M / Tran Minh, M L / Leleu, F / Hassid, D

    Journal of visceral surgery

    2020  Band 157, Heft 3S1, Seite(n) S51–S57

    Abstract: The symptoms associated with COVID-19 are mainly characterized by a triad composed of fever, dry cough and dyspnea. However, digestive symptoms have also been reported. At first considered as infrequent, they in fact seem to affect more than half of ... ...

    Abstract The symptoms associated with COVID-19 are mainly characterized by a triad composed of fever, dry cough and dyspnea. However, digestive symptoms have also been reported. At first considered as infrequent, they in fact seem to affect more than half of patients. The symptoms mainly include anorexia, diarrhea, nausea and/or vomiting and abdominal pain. Even though prognosis is associated with lung injury, digestive symptoms seem significantly more frequent in patients presenting with severe COVID-19 infection. Digestive presentations, which may be isolated or which can precede pulmonary symptoms, have indeed been reported, with diarrhea as a leading clinical sign. The main biological abnormalities that can suggest COVID-19 infection at an early stage are lymphopenia, elevated CRP and heightened ASAT transaminases. Thoraco-abdominal scan seems useful as a means of on the one hand ruling out digestive pathology not connected with coronavirus and on the other hand searching for pulmonary images consistent with COVID-19 infection. No data exist on the value of digestive endoscopy in cases of persistent digestive symptoms. Moreover, the endoscopists may themselves be at significant risk of contamination. Fecal-oral transmission of the infection is possible, especially insofar as viral shedding in stools seems frequent and of longer duration than at the ENT level, including in patients with negative throat swab and without digestive symptoms. In some doubtful cases, virologic assessment of stool samples can yield definitive diagnosis. In the event of prolonged viral shedding in stools, a patient's persistent contagiousness is conceivable but not conclusively established. Upcoming serology should enable identification of the patients having been infected by the COVID-19 epidemic, particularly among previously undetected pauci-symptomatic members of a health care staff. Resumption of medico-surgical activity should be the object of a dedicated strategy preceding deconfinement.
    Mesh-Begriff(e) COVID-19 ; Coronavirus Infections/complications ; Digestive System Diseases/etiology ; Digestive System Diseases/surgery ; Digestive System Surgical Procedures ; Humans ; Pandemics ; Pneumonia, Viral/complications
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-04-24
    Erscheinungsland France
    Dokumenttyp Journal Article ; Review
    ISSN 1878-7886
    ISSN (online) 1878-7886
    DOI 10.1016/j.jviscsurg.2020.04.017
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.

    du Rusquec, P / Guimbaud, R / Le Malicot, K / Gornet, J-M / Nguyen, S / Lecomte, T / Khemissa-Akouz, F / Perrier, H / Bouché, O / Paoletti, X / Le Tourneau, C

    ESMO open

    2023  Band 8, Heft 4, Seite(n) 101616

    Abstract: Background: Precision medicine trials disrupted the paradigm of randomized controlled trials in large populations. Patient selection may be based on molecular alterations rather than on primary tumor location. In small patient populations, the growth ... ...

    Abstract Background: Precision medicine trials disrupted the paradigm of randomized controlled trials in large populations. Patient selection may be based on molecular alterations rather than on primary tumor location. In small patient populations, the growth modulation index (GMI) has been developed to evaluate treatment efficacy by using each patient as its own control. The FFCD 0307 randomized phase III trial compared two sequences of chemotherapy in advanced gastric cancer, which represents a unique opportunity to evaluate the relevance of the GMI.
    Patients and methods: In the FFCD 0307 trial, patients with advanced gastric cancer were randomized between two chemotherapy sequences [ECX followed by FOLFIRI at disease progression (arm A) versus FOLFIRI followed by ECX (arm B)]. GMI was defined as the ratio of the progression-free survival on second treatment (PFS2) to the time to progression on first treatment (TTP1). Sequence benefit was defined as a GMI exceeding 1.3 (GMI-high). GMI was correlated with overall survival (OS). OS1 and OS2 were measured from first randomization and second-line failure to death.
    Results: Four hundred and sixteen patients were randomized (209 in arm A, 207 in arm B). One hundred and seventy-five patients (42%) received the two sequences and were assessable for GMI (97 in arm A, 79 in arm B). The median GMI was higher in arm A than in arm B (0.62 versus 0.47, P = 0.04). Patients with a high GMI had a longer OS1 (median 14.9 versus 11.5 months, NS). Median OS2 was doubled in the GMI-high group (3.4 versus 1.6 months, NS).
    Conclusion: GMI analyses suggest that ECX followed by FOLFIRI might represent a better therapeutic strategy than FOLFIRI followed by ECX. High GMI was associated with prolonged survival.
    Mesh-Begriff(e) Humans ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/pathology ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use ; Leucovorin/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Treatment Outcome ; Randomized Controlled Trials as Topic
    Chemische Substanzen Fluorouracil (U3P01618RT) ; Leucovorin (Q573I9DVLP)
    Sprache Englisch
    Erscheinungsdatum 2023-08-04
    Erscheinungsland England
    Dokumenttyp Clinical Trial, Phase III ; Journal Article
    ISSN 2059-7029
    ISSN (online) 2059-7029
    DOI 10.1016/j.esmoop.2023.101616
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel: What do surgeons need to know about the digestive disorders and paraclinical abnormalities induced by COVID-19?

    Gornet, J-M / Tran Minh, M L / Leleu, F / Hassid, D

    J Visc Surg

    Abstract: The symptoms associated with COVID-19 are mainly characterized by a triad composed of fever, dry cough and dyspnea. However, digestive symptoms have also been reported. At first considered as infrequent, they in fact seem to affect more than half of ... ...

    Abstract The symptoms associated with COVID-19 are mainly characterized by a triad composed of fever, dry cough and dyspnea. However, digestive symptoms have also been reported. At first considered as infrequent, they in fact seem to affect more than half of patients. The symptoms mainly include anorexia, diarrhea, nausea and/or vomiting and abdominal pain. Even though prognosis is associated with lung injury, digestive symptoms seem significantly more frequent in patients presenting with severe COVID-19 infection. Digestive presentations, which may be isolated or which can precede pulmonary symptoms, have indeed been reported, with diarrhea as a leading clinical sign. The main biological abnormalities that can suggest COVID-19 infection at an early stage are lymphopenia, elevated CRP and heightened ASAT transaminases. Thoraco-abdominal scan seems useful as a means of on the one hand ruling out digestive pathology not connected with coronavirus and on the other hand searching for pulmonary images consistent with COVID-19 infection. No data exist on the value of digestive endoscopy in cases of persistent digestive symptoms. Moreover, the endoscopists may themselves be at significant risk of contamination. Fecal-oral transmission of the infection is possible, especially insofar as viral shedding in stools seems frequent and of longer duration than at the ENT level, including in patients with negative throat swab and without digestive symptoms. In some doubtful cases, virologic assessment of stool samples can yield definitive diagnosis. In the event of prolonged viral shedding in stools, a patient's persistent contagiousness is conceivable but not conclusively established. Upcoming serology should enable identification of the patients having been infected by the COVID-19 epidemic, particularly among previously undetected pauci-symptomatic members of a health care staff. Resumption of medico-surgical activity should be the object of a dedicated strategy preceding deconfinement.
    Schlagwörter covid19
    Verlag WHO
    Dokumenttyp Artikel
    Anmerkung WHO #Covidence: #116695
    Datenquelle COVID19

    Kategorien

  5. Artikel ; Online: Que doivent savoir les chirurgiens à propos des troubles digestifs et des anomalies paracliniques induits par le COVID 19 ?

    Gornet, J.-M. / Tran Minh, M.L. / Leleu, F. / Hassid, D.

    Journal de Chirurgie Viscérale

    2020  Band 157, Heft 3, Seite(n) S52–S59

    Schlagwörter Surgery ; covid19
    Sprache Französisch
    Verlag Elsevier BV
    Erscheinungsland us
    Dokumenttyp Artikel ; Online
    ZDB-ID 2541648-0
    ISSN 1878-786X ; 0021-7697
    ISSN 1878-786X ; 0021-7697
    DOI 10.1016/j.jchirv.2020.04.013
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: What do surgeons need to know about the digestive disorders and paraclinical abnormalities induced by COVID-19?

    Gornet, J.-M. / Tran Minh, M.L. / Leleu, F. / Hassid, D.

    Journal of Visceral Surgery

    2020  Band 157, Heft 3, Seite(n) S51–S57

    Schlagwörter General Medicine ; covid19
    Sprache Englisch
    Verlag Elsevier BV
    Erscheinungsland us
    Dokumenttyp Artikel ; Online
    ISSN 1878-7886
    DOI 10.1016/j.jviscsurg.2020.04.017
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Prognosis and molecular characteristics of IBD-associated colorectal cancer: Experience from a French tertiary-care center.

    Hammoudi, N / Lehmann-Che, J / Lambert, J / Amoyel, M / Maggiori, L / Salfati, D / Tran Minh, M L / Baudry, C / Asesio, N / Poirot, B / Lourenco, N / Corte, H / Allez, M / Aparicio, T / Gornet, J M

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

    2023  Band 55, Heft 9, Seite(n) 1280–1287

    Abstract: Background: Little is known about the prognosis of colorectal cancer associated with inflammatory bowel disease (CRC-IBD) in a real-world cohort in France.: Methods: We conducted a retrospective observational study including all patients presenting ... ...

    Abstract Background: Little is known about the prognosis of colorectal cancer associated with inflammatory bowel disease (CRC-IBD) in a real-world cohort in France.
    Methods: We conducted a retrospective observational study including all patients presenting CRC-IBD in a French tertiary center.
    Results: Among 6510 patients, the rate of CRC was 0.8% with a median delay of 19.5 years after IBD diagnosis (median age 46 years, ulcerative colitis 59%, initially localized tumor 69%). There was a previous exposure to immunosuppressants (IS) in 57% and anti-TNF in 29% of the cases. A RAS mutation was observed in only 13% of metastatic patients. OS of the whole cohort was 45 months. OS and PFS of synchronous metastatic patients was 20.4 months and 8.5 months respectively. Among the patients with localized tumor those previously exposed to IS had a better PFS (39 months vs 23 months; p = 0.05) and OS (74 vs 44 months; p = 0.03). The IBD relapse rate was 4%. No unexpected chemotherapy side-effect was observed CONCLUSIONS: OS of CRC-IBD is poor in metastatic patients although IBD is not associated with under-exposure or increased toxicity to chemotherapy. Previous IS exposure may be associated with a better prognosis.
    Mesh-Begriff(e) Humans ; Middle Aged ; Crohn Disease/complications ; Tumor Necrosis Factor Inhibitors ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/complications ; Risk Factors ; Neoplasm Recurrence, Local ; Inflammatory Bowel Diseases/complications ; Inflammatory Bowel Diseases/drug therapy ; Inflammatory Bowel Diseases/pathology ; Prognosis ; Immunosuppressive Agents
    Chemische Substanzen Tumor Necrosis Factor Inhibitors ; Immunosuppressive Agents
    Sprache Englisch
    Erscheinungsdatum 2023-03-04
    Erscheinungsland Netherlands
    Dokumenttyp Observational Study ; Journal Article
    ZDB-ID 1459373-7
    ISSN 1878-3562 ; 1125-8055
    ISSN (online) 1878-3562
    ISSN 1125-8055
    DOI 10.1016/j.dld.2023.02.011
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel: Dépistage du cancer colorectal.

    Gornet, J-M

    Pathologie-biologie

    2004  Band 52, Heft 3, Seite(n) 115–116

    Titelübersetzung Detection and mass - screening programs of colorectal cancer.
    Mesh-Begriff(e) Aged ; Colorectal Neoplasms/diagnosis ; Colorectal Neoplasms/epidemiology ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; France/epidemiology ; Humans ; Mass Screening ; Middle Aged ; Occult Blood ; Risk Factors
    Sprache Französisch
    Erscheinungsdatum 2004-04
    Erscheinungsland France
    Dokumenttyp Journal Article ; Review
    ZDB-ID 207652-4
    ISSN 0369-8114
    ISSN 0369-8114
    DOI 10.1016/j.patbio.2003.12.004
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Erratum à l'article « Étude prospective de la qualité de vie après une CHIP par oxaliplatine pour carcinose péritonéale » [Bull. Cancer 97 (2010) 1053-60].

    Lim, C / Tordjman, D / Gornet, J-M / Nemeth, J / Valleur, P / Pocard, Marc

    Bulletin du cancer

    2016  Band 103, Heft 7-8, Seite(n) 707

    Titelübersetzung Erratum to "Prospective study of quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using oxaliplatin for peritoneal carcinomatosis" [Bull. Cancer 97 (2010) 1053-60].
    Sprache Französisch
    Erscheinungsdatum 2016-07
    Erscheinungsland France
    Dokumenttyp Published Erratum
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/j.bulcan.2016.05.009
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Loss of SMARCB1 expression in colon carcinoma.

    Melloul, S / Mosnier, J-F / Masliah-Planchon, J / Lepage, C / Le Malicot, K / Gornet, J-M / Edeline, J / Dansette, D / Texereau, P / Delattre, O / Laurent Puig, P / Taieb, J / Emile, J-F

    Cancer biomarkers : section A of Disease markers

    2020  Band 27, Heft 3, Seite(n) 399–406

    Abstract: SMARCB1 is a tumor suppressor gene, which is part of SWI/SNF complex involved in transcriptional regulation. Recently, loss of SMARCB1 expression has been reported in gastrointestinal carcinomas. Our purpose was to evaluate the incidence and prognostic ... ...

    Abstract SMARCB1 is a tumor suppressor gene, which is part of SWI/SNF complex involved in transcriptional regulation. Recently, loss of SMARCB1 expression has been reported in gastrointestinal carcinomas. Our purpose was to evaluate the incidence and prognostic value of SMARCB1 loss in colon carcinoma (CC). Patients with stage III CC (n= 1695), and a second cohort of 23 patients with poorly differentiated CC were analyzed. Immunohistochemistry for SMARCB1 was performed on tissue microarrays, and cases with loss of expression were controlled on whole sections. Loss of SMARCB1 was compared with the clinico-pathological and molecular characteristics, and the prognostic value was evaluated. Loss of SMARCB1 was identified in 12 of 1695 (0.7%) patients with stage III CC. Whole section controls showed a complete loss in only one of these cases, corresponding to a medullary carcinoma. SMARCB1 loss was not associated with histological grade, tumor size nor survival. In the cohort of poorly differentiated CC, we detected 2/23 (8.7%) cases with loss of SMARCB1; one was rhabdoid while the other had medullary and mucinous histology. These 2 cases were deficient for MisMatched Repair (dMMR) and mutated for BRAF. SMARCB1 loss is rare in stage III CC, but appears more frequent in poorly differentiated CC.
    Mesh-Begriff(e) Adult ; Aged ; Colonic Neoplasms/genetics ; Colonic Neoplasms/metabolism ; Colonic Neoplasms/pathology ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Neoplasm Staging ; SMARCB1 Protein/biosynthesis ; SMARCB1 Protein/deficiency ; SMARCB1 Protein/genetics ; SMARCB1 Protein/metabolism ; Young Adult
    Chemische Substanzen SMARCB1 Protein ; SMARCB1 protein, human
    Sprache Englisch
    Erscheinungsdatum 2020-02-21
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article
    ZDB-ID 2203517-5
    ISSN 1875-8592 ; 1574-0153 ; 1875-8592
    ISSN (online) 1875-8592 ; 1574-0153
    ISSN 1875-8592
    DOI 10.3233/CBM-190287
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang